TY - JOUR
T1 - Innovating Cancer Care Delivery
T2 - the Example of the 4R Oncology Model for Colorectal Cancer Patients
AU - Trosman, Julia
AU - Weldon, Christine
AU - Kircher, Sheetal
AU - Gradishar, William
AU - Benson, Al
N1 - Funding Information:
2011;103(2):117–28. https://doi.org/10.1093/jnci/ djq495. Shanafelt TD, Gradishar WJ, Kosty M, Satele D, Chew H, Horn L, et al. Burnout and career satisfaction among US oncologists. J Clin Oncol. 2014;32(7):678–86. https://doi.org/10.1200/JCO.2013.51.8480. Spinks T, Albright HW, Feeley TW, Walters R, Burke TW, Aloia T, et al. Ensuring quality cancer care: a follow-up review of the Institute of Medicine’s 10 recommendations for improving the quality of cancer care in America. Cancer. 2012;118(10):2571–82. https:// doi.org/10.1002/cncr.26536. Levit L, Balogh E, Nass S, Ganz PA, editors. Delivering high-quality cancer care: charting a new course for a system in crisis. Washington (DC); 2013. Shih YC, Ganz PA, Aberle D, Abernethy A, Bekelman J, Brawley O, et al. Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol. 2013;31(32):4151–7. https://doi.org/10.1200/ JCO.2013.51.0651. Freund KM, Battaglia TA, Calhoun E, Darnell JS, Dudley DJ, Fiscella K, et al. Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. J Natl Cancer Inst. 2014;106(6):dju115. https://doi.org/10.1093/jnci/dju115. Rodday AM, Parsons SK, Snyder F, Simon MA, Llanos AA, Warren-Mears V, et al. Impact of patient navigation in eliminating economic disparities in cancer care. Cancer. 2015;121(22):4025–34. https://doi.org/10. 1002/cncr.29612. Establishing effective patient navigation programs in oncology: proceedings of a workshop. The National Academies Collection: Reports funded by National Institutes of Health. Washington (DC); 2018. Kuntz G, Tozer J, Snegosky J, Fox J, Neumann K. Michigan Oncology Medical Home Demonstration Project: first-year results. J Oncol Pract. 2014;10(2):104. https:// doi.org/10.1200/JOP.2013.001109. Colligan EM, Ewald E, Keating NL, Parashuram S, Spafford M, Ruiz S, et al. Two innovative cancer care programs have potential to reduce utilization and spending. Med Care. 2017;55(10):873–8. https://doi. org/10.1097/MLR.0000000000000795. Liu B, Song Y, Liu D. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. J Hematol Oncol. 2017;10(1):174. https://doi.org/10.1186/s13045-017-0541-9. Kroschinsky F, Stolzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21(1):89. https://doi.org/10.1186/s13054-017-1678-1. Cukier P, Santini FC, Scaranti M, Hoff AO. Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer. 2017;24(12):T331–T47. https://doi.org/10. 1530/ERC-17-0358. Lee L, Cheung WY, Atkinson E, Krzyzanowska MK. Impact of comorbidity on chemotherapy use and
Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Care delivery innovation is necessary to address the growing complexity of cancer care across specialties and integrate new diagnostics, treatments, and services into care delivery. Informed by Cancer Care Delivery Research (CCDR), multilevel intervention research, and other disciplines, this article describes the 4-step cancer care delivery innovation cycle. The cycle guides collaborative efforts of cancer clinicians, researchers, patients, and other stakeholders to systematically define care delivery problems and formulate, test, and implement care innovations to effectively address problems. We illustrate the 4 steps of the innovation cycle with the example of developing the 4R Oncology Model for colorectal cancer (4R is Right Information and Right Care for the Right Patient at the Right Time). The 4R is a multilevel intervention informed by CCDR, the team science, and lessons learned from other models, such as survivorship care planning. We offer additional considerations for balancing the need to innovate with concerns about constrained resources and overextended workforce. We suggest to focus on care delivery models which are synergistic with other efforts and do not require extensive information systems support in earlier cycles of development.
AB - Care delivery innovation is necessary to address the growing complexity of cancer care across specialties and integrate new diagnostics, treatments, and services into care delivery. Informed by Cancer Care Delivery Research (CCDR), multilevel intervention research, and other disciplines, this article describes the 4-step cancer care delivery innovation cycle. The cycle guides collaborative efforts of cancer clinicians, researchers, patients, and other stakeholders to systematically define care delivery problems and formulate, test, and implement care innovations to effectively address problems. We illustrate the 4 steps of the innovation cycle with the example of developing the 4R Oncology Model for colorectal cancer (4R is Right Information and Right Care for the Right Patient at the Right Time). The 4R is a multilevel intervention informed by CCDR, the team science, and lessons learned from other models, such as survivorship care planning. We offer additional considerations for balancing the need to innovate with concerns about constrained resources and overextended workforce. We suggest to focus on care delivery models which are synergistic with other efforts and do not require extensive information systems support in earlier cycles of development.
KW - 4R Oncology Model
KW - Cancer care delivery
KW - Care delivery innovation
KW - Care delivery models
KW - Care delivery redesign
KW - Project management in care delivery
KW - Systems engineering in cancer care delivery
UR - http://www.scopus.com/inward/record.url?scp=85061292864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061292864&partnerID=8YFLogxK
U2 - 10.1007/s11864-019-0608-7
DO - 10.1007/s11864-019-0608-7
M3 - Review article
C2 - 30741356
AN - SCOPUS:85061292864
SN - 1527-2729
VL - 20
JO - Current treatment options in oncology
JF - Current treatment options in oncology
IS - 2
M1 - 11
ER -